Sir, We read with great interest the article, "A distinct clinicopathological presentation of cutaneous dermatophytosis mimicking autoimmune blistering disorder" which appeared in the Indian Journal of Dermatology, Issue 5, Volume 63. [1] The authors presented a case of an extensive dermatophytosis that simulated clinically, histologically, and immunologically a bullous pemphigoid. The authors concluded that the possible mechanism would be a molecular mimicry that could trigger a hypersensitive response from the stratum corneum to the dermoepidermal junction and try to make a distinction with previous reports of bullous tinea corporis. We agree with the authors that it is not a clinical variety of this last entity since the cases of tinea bullosa referred by the authors are completely different in several aspects. The cases of bullous tinea corporis commonly present fungi in the blister cavity, also have a more rapid evolution (around a week or less) and are frequently localized, while the cases of bullous pemphigoid are chronic and generally disseminated; bullous tinea has intraepidermal blisters, while pemphigoid develops subepidermal blisters. Moreover, there are no deposits of antibodies to direct immunofluorescence in the former, an aspect frequently seen in the latter.
However, we are not in agreement that the present case is an example of dermatophytosis that "simulates" a bullous pemphigoid, since it shows all the diagnostic criteria of the disease (clinical, histological, and immunological). We consider that the patient presents a typical bullous pemphigoid that responded favorably to systemic steroids and that subsequently presented a tinea incognito related to systemic steroids. A similar case was reported by Liu and Shen, [2] showing a female patient with bullous pemphigoid, treated with potent topical steroids, developing a tinea incognito. In the present case, the patient might have had a mild cutaneous dermatophytosis that had not been diagnosed; hence, it is advisable to perform a detailed examination before starting topical and/or systemic steroids, in order to avoid diagnostic biases.
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